Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients

Journal of Chemotherapy

Volumn 8, Issue 2, 1996, Pages 159-164

  Hasturk S ^a,d   Tastepe, I ^b   Unlu M ^b   Cetin G ^b   Baris, Y I ^c  

^a CUKUROVA UNIVERSITY   (Turkey)

^b Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Malignant pleural mesothelioma (MPM); Mesothelioma; Multimodal treatment; Pleurectomy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; MITOMYCIN C;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG CANCER; MESOTHELIOMA; NAUSEA; PLEURECTOMY; VOMITING;

EID: 0029919693     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.2.159     Document Type: Article

References (21)

1. Hansen AK, Hansen HH. Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 1991; 28:319-330.
2. Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD. Experimental and clinical activity of mitomycin C and cis-diamine-dichloroplatinum in malignant mesothelioma. Cancer Res, 1984; 44:1688-1692.
3. Sklarin NT, Chahinian AP, Feuer EJ, Lahman AL, Szrajer L, Holland JF. Augmentation of activity of cis-diammine-dichloroplatinium (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 1988; 48:64-67.
4. Sridhar KS, Doria R, Raub WA, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer, 1992; 70:2969-2979.
5. Harvey JC, Fleischman EH, Kagan AR, Streeter OE. Malignant pleural mesothelioma: A survival study. J Surg Oncol, 1990; 45:40-42.
6. Rusch VW. Diagnosis and treatment of pleural mesothelioma. Semin Surg Oncol, 1990; 6:279-285.
7. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. The role of surgery in diffuse mesothelioma of the pleura. Semin Oncol, 1981; 8:321-328.
8. BMDP Statistical Software Manual. Los Angeles: University of California Press. 1992; 2:795-824.
9. Tammilehto L, Maasilta P, Kostianinen S, Holsti LR, Mattson K. Diagnosis and prognostic factors in malignant pleural mesothelioma: A retrospective analysis of sixty-five patients. Respiration, 1992; 59:129-135.
10. Chailleux E, Dabouis G, Pioche D, Lajarte M, Lajarte AY, Rembeaux A, Germaud P. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest, 1988; 93:159-162.
11. Van Gelder T, Damhuis RAM, Hoogsteden HC . Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J, 1994; 7:1035-1038.
12. Boutin C, Viallat JR, Rey F, Astoul PH. Clinical diagnosis of pleural mesothelioma. Eur Respir Rev, 1993; 3:18-21.
13. Selçuk ZT, Çöplü L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Chest, 1992; 102:790-796.
14. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 1991; 102:1-9.
15. Sugarbaker DJ, Heher EC, Lee TH. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg,1991; 102:10-15.
16. Ruffie P. Mesothelioma chemotherapy. Eur Respir Rev, 1993; 3:199-203.
17. Brancatisano RP, Joseph MG, McCaughan BC. Pleurectomy for mesothelioma. Med J Aust, 1991; 154:455-60.
18. McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Surg, 1982; 84:834-42.
19. Chahinian AP. The nude mouse model in mesothelioma research and therapy. Eur Respir Rev, 1993; 3:204-207.
20. Hand AM, Husgafvel-Pursiainen K, Tammilehto L, Mattson K, Linnainmaa K. Malignant mesothelioma: The antiproliferative effect of cytokine combinations on three human mesothelioma cell lines. Cancer Lett, 1991; 58:205-210.
21. Tansan S, Emri S, Selçuk T, Koç Y et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology, 1994; 51:348-351.